RegNext | Daily Europe Radar | EOD Briefing | Friday 29 May 2026
The Medicines and Healthcare products Regulatory Agency just authorised Rilzabrutinib for immune thrombocytopenia. Here's what it means for the UK pharmaceutical landscape.
Today's regulatory environment is defined by high-impact enforcement and new structural frameworks across the United Kingdom and the European Union. In Great Britain, the MHRA has successfully executed its largest ever seizure of unlicensed medicines while simultaneously advancing clinical approvals. On the continent, the European Commission is refining digital governance and market resilience. With five updates from EU institutions and four from European member states today, and 49 deadlines approaching within the week, compliance teams face a dense schedule of strategic policy shifts and enforcement actions.
1️⃣ [#1] Medicines and Healthcare products Regulatory Agency — Rilzabrutinib authorised for immune thrombocytopenia
The regulator granted marketing authorisation for treating adults when prior treatments have been insufficient
Pharmaceutical companies and healthcare providers treating chronic blood disorders
Clinical integration of the new treatment option begins under the new authorisation
2️⃣ [#3] European Commission — Targeted consultation on Digital Services Act trusted flaggers
A draft set of guidelines has been released to define the status and roles of trusted flaggers
Digital service providers and entities applying for trusted flagger status
Stakeholders are invited to submit feedback to refine the final regulatory guidelines
3️⃣ [#5] BaFin — Mandatory measures ordered for CRONBANK Aktiengesellschaft
The regulator mandated a measures package covering business organization and anti-money laundering prevention
The bank's executive board and internal compliance departments
A special representative will now oversee the implementation of capital and organizational requirements
Beyond the primary highlights, the Department of Health and Social Care issued guidance on the Community Pharmacy Contractual Framework for 2026 to 2027. The Office of Rail and Road introduced an action plan for artificial intelligence safety, while the Department for Science, Innovation and Technology announced plans to toughen protections for subsea cables. Additionally, the Central Bank of Ireland issued a warning regarding a clone firm, while Sveriges Riksbank highlighted stability risks stemming from conflict in the Middle East. These developments underscore a broad regulatory focus on technological safety, financial integrity, and public health security.
Full analysis in today's RegNext Daily Europe Radar.
